Impact of compound mutations I1171N + F1174I and I1171N + L1198H on the structure of ALK in NSCLC pathogenesis: atomistic insights

References

• Abdullahi, M., Olotu, F. A., & Soliman, M. E. (2018). Allosteric inhibition abrogates dysregulated LFA-1 activation: Structural insight into mechanisms of diminished immunologic disease. Computational Biology and Chemistry, 73, 49–56. https://doi.org/10.1016/j.compbiolchem.2018.02.002
   PubMed Web of Science ®Google Scholar
• Agoni, C., Salifu, E. Y., Munsamy, G., Olotu, F. A., & Soliman, M. (2019). CF < inf > 3</inf>-pyridinyl substitution on antimalarial therapeutics: probing differential ligand binding and dynamical inhibitory effects of a novel triazolopyrimidine-based inhibitor on plasmodium falciparum dihydroorotate dehydrogenase. Chemistry & Biodiversity, 16(2), e1900365. https://doi.org/10.1002/cbdv.201900365
   Google Scholar
• Awad, M. M. (2013). Acquired resistance to crizotinib from a mutation in CD74 – ROS1. The New England Journal of Medicine, 368(25), 2395-2401. https://doi.org/10.1056/nejmoa1215530
   Google Scholar
• Caravella, J. A., Lin, J., Diebold, R. B., Campbell, A.-M., Ericsson, A., Gustafson, G., Wang, Z., Castro, J., Clarke, A., Gotur, D., Josephine, H. R., Katz, M., Kershaw, M., Yao, L., Toms, A. V., Barr, K. J., Dinsmore, C. J., Walker, D., Ashwell, S., & Lu, W. (2020). Structure-based design and identification of FT-2102 (Olutasidenib), a potent mutant-selective IDH1 inhibitor. Journal of Medicinal Chemistry, 63(4), 1612–1623. https://doi.org/10.1021/acs.jmedchem.9b01423
   PubMed Web of Science ®Google Scholar
• Choi, Y. L. (2010). EML4-ALK Mutations in lung cancer that confer resistance to ALK inhibitors. The New England Journal of Medicine, 363(18), 1734-1739. https://doi.org/10.1056/nejmoa1007478
   Google Scholar
• Dagogo-Jack, I. (2019). Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity. Clinical Cancer Research, 25(22), 6662–6670. https://doi.org/10.1158/1078-0432.CCR-19-1436
   Google Scholar
• Doebele, R. C. (2012). Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clinical Cancer Research, 18(5), 1472–1482. https://doi.org/10.1158/1078-0432.CCR-11-2906
   Google Scholar
• Fujita, S., Masago, K., Katakami, N., & Yatabe, Y. (2016). Transformation to SCLC after treatment with the ALK inhibitor alectinib. Journal of Thoracic Oncology, 11(6), e67-e72. https://doi.org/10.1016/j.jtho.2015.12.105
   Google Scholar
• Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo-Jack, I., Gadgeel, S., Schultz, K., Singh, M., Chin, E., Parks, M., Lee, D., DiCecca, R. H., Lockerman, E., Huynh, T., Logan, J., Ritterhouse, L. L., Le, L. P., … Shaw, A. T. (2016). Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK -rearranged lung cancer. Cancer Discovery, 6(10), 1118–1133. https://doi.org/10.1158/2159-8290.CD-16-0596
   PubMed Web of Science ®Google Scholar
• Ganesan, A., Coote, M. L., & Barakat, K. (2017). Molecular dynamics-driven drug discovery: Leaping forward with confidence. Drug Discovery Today, 22(2), 249–269. https://doi.org/10.1016/j.drudis.2016.11.001
   PubMed Web of Science ®Google Scholar
• Guan, J., Yamazaki, Y., Chand, D., van Dijk, J., Ruuth, K., Palmer, R., & Hallberg, B. (2017). Novel mechanisms of ALK activation revealed by analysis of the Y1278S neuroblastoma mutation. Cancers (Basel), 9(12), 149. https://doi.org/10.3390/cancers9110149
   PubMedGoogle Scholar
• Hallberg, B., & Palmer, R. H. (2013). Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nature Reviews Cancer, 13(10), 685–700. https://doi.org/10.1038/nrc3580
   PubMed Web of Science ®Google Scholar
• Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A., Flanagan, J., Chan, E., Varella-Garcia, M., Aisner, D. L., Vaishnavi, A., Ou, S.-H I., Collisson, E. A., Ichihara, E., Mack, P. C., … Bivona, T. G. (2015). RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nature Medicine, 21(9), 1038–1047. doi: 10.1038/nm.3930.
   PubMed Web of Science ®Google Scholar
• Hu, G., Yan, W., Zhou, J., & Shen, B. (2014). Residue interaction network analysis of Dronpa and a DNA clamp. Journal of Theoretical Biology, 348, 55–64. https://doi.org/10.1016/j.jtbi.2014.01.023
   PubMed Web of Science ®Google Scholar
• Huang, H. (2018). Anaplastic lymphoma kinase (Alk) receptor tyrosine kinase: A catalytic receptor with many faces. International Journal of Molecular Sciences, 19(11), 3448. https://doi.org/10.3390/ijms1911
   PubMed Web of Science ®Google Scholar
• Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., Drew, L., Saeh, J. C., Crosby, K., Sequist, L. V., Iafrate, A. J., & Engelman, J. A. (2012). Cancer: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Science Translational Medicine, 4(120), 120ra17. https://doi.org/10.1126/scitranslmed.3003316
   Google Scholar
• Leonetti, A., & Tiseo, M. (2021). Systemic treatments other than TKI: Reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC. In Therapeutic strategies to overcome ALK resistance in Cancer.
   Google Scholar
• Munsamy, G., Agoni, C., & Soliman, M. E. S. (2018). A dual target of Plasmepsin IX and X: Unveiling the atomistic superiority of a core chemical scaffold in malaria therapy. Journal of Cell Biology, 120(5), 1–12. https://doi.org/10.1002/jcb.28062
   Google Scholar
• Okada, K., Araki, M., Sakashita, T., Ma, B., Kanada, R., Yanagitani, N., Horiike, A., Koike, S., Oh-hara, T., Watanabe, K., Tamai, K., Maemondo, M., Nishio, M., Ishikawa, T., Okuno, Y., Fujita, N., & Katayama, R. (2019). Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine, 41, 105–119. 2019, https://doi.org/10.1016/j.ebiom.2019.01.019
   PubMed Web of Science ®Google Scholar
• Pailler, E. (2019). Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non–small-cell lung cancer. Clinical Cancer Research, 25(22), 6671–6682. https://doi.org/10.1158/1078-0432.CCR-19-1176
   Google Scholar
• Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612. https://doi.org/10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Raabe, G. (2017). Molecular simulation studies on thermophysical properties.
   Google Scholar
• Recondo, G. (2020). Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clinical Cancer Research, 26(1), 242–255. https://doi.org/10.1158/1078-0432.CCR-19-1104
   Google Scholar
• Rolta, R., Yadav, R., Salaria, D., Trivedi, S., Imran, M., Sourirajan, A., Baumler, D. J., & Dev, K. (2021). In silico screening of hundred phytocompounds of ten medicinal plants as potential inhibitors of nucleocapsid phosphoprotein of COVID-19: an approach to prevent virus assembly. Journal of Biomolecular Structure & Dynamics, 39(18), 7017–7034. https://doi.org/10.1080/07391102.2020.1804457
   PubMed Web of Science ®Google Scholar
• Salaria, D., Rolta, R., Patel, C. N., Dev, K., Sourirajan, A., & Kumar, V. (2021). In vitro and in silico analysis of Thymus serpyllum essential oil as bioactivity enhancer of antibacterial and antifungal agents. Journal of Biomolecular Structure and Dynamics, 1–20. 0 https://doi.org/10.1080/07391102.2021.1943530
   Google Scholar
• Salifu, E. Y., Agoni, C., Olotu, F. A., & Soliman, M. E. S. (2020). Triple mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives. Computational Biology and Chemistry, 85, 107204. https://doi.org/10.1016/j.compbiolchem.2020.107204.
   PubMed Web of Science ®Google Scholar
• Salifu, E. Y., Agoni, C., Olotu, F. A., Dokurugu, Y. M., & Soliman, M. E. S. (2019). Halting ionic shuttle to disrupt the synthetic machinery—Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis. Journal of Cellular Biochemistry, 120(9), 16108-16119. https://doi.org/10.1002/jcb.28891
   Google Scholar
• Salomon-Ferrer, R., Götz, A. W., Poole, D., Grand, S. L., & Walker, R. C. (2013). Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh ewald. Journal of Chemical Theory and Computation, 9(9), 3878–3888. https://doi.org/10.1021/ct400314y
   PubMed Web of Science ®Google Scholar
• Shaw, A. T. (2017). Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. The Lancet Oncology, 18(12), 1590-1599. https://doi.org/10.1016/S1470-2045(17)30680-0
   Google Scholar
• Shaw, A. T., & Engelman, J. A. (2013). ALK in lung cancer: Past, present, and future. Journal of Clinical Oncology, 31(8), 1105–1111. https://doi.org/10.1200/JCO.2012.44.5353
   PubMed Web of Science ®Google Scholar
• Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S-i., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., & Mano, H. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561–566. https://doi.org/10.1038/nature05945
   PubMed Web of Science ®Google Scholar
• Solomon, B. J. (2018). Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. The Lancet Oncology, 19(12), 1654-1667. https://doi.org/10.1016/S1470-2045(18)30649-1
   Google Scholar
• Teilum, K., Olsen, J. G., & Kragelund, B. B. (2011). Protein stability, flexibility and function. Biochimica et Biophysica Acta - Proteins and Proteomics, 1814(8), 969-976. https://doi.org/10.1016/j.bbapap.2010.11.005
   Google Scholar
• White, S. H., & Wimley, W. C. (1999). Membrane protein folding and stability: Physical principles. Annual Review of Biophysics and Biomolecular Structure, 28(1), 319–365. https://doi.org/10.1146/annurev.biophys.28.1
   PubMedGoogle Scholar
• Xue, W., Jin, X., Ning, L., Wang, M., Liu, H., & Yao, X. (2013). Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis . Journal of Chemical Information and Modeling, 53(1), 210–222. https://doi.org/10.1021/ci300541c
   PubMed Web of Science ®Google Scholar
• Yamada, T. (2012). Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clinical Cancer Research, 18(13), 3592–3602. https://doi.org/10.1158/1078-0432.CCR-11-2972
   Google Scholar
• Yoda, S., Lin, J. J., Lawrence, M. S., Burke, B. J., Friboulet, L., Langenbucher, A., Dardaei, L., Prutisto-Chang, K., Dagogo-Jack, I., Timofeevski, S., Hubbeling, H., Gainor, J. F., Ferris, L. A., Riley, A. K., Kattermann, K. E., Timonina, D., Heist, R. S., Iafrate, A. J., Benes, C. H., … Shaw, A. T. (2018). Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discovery, 8(6), 714–729. https://doi.org/10.1158/2159-8290.CD-17-1256
   PubMed Web of Science ®Google Scholar
• Yun, M. R., Lim, S. M., Kim, S.-K., Choi, H. M., Pyo, K.-H., Kim, S. K., Lee, J. M., Lee, Y. W., Choi, J. W., Kim, H. R., Hong, M. H., Haam, K., Huh, N., Kim, J.-H., Kim, Y. S., Shim, H. S., Soo, R. A., Shih, J.-Y., Yang, J. C.-H., Kim, M., & Cho, B. C. (2018). Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors. Cancer Research, 78(12), 3350–3362. https://doi.org/10.1158/0008-5472.CAN-17-3146
   PubMed Web of Science ®Google Scholar
• Zou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., Tang, R. W., Wang, H., Tsaparikos, K., Wang, J., Timofeevski, S., Katayama, R., Dinh, D. M., Lam, H., Lam, J. L., Yamazaki, S., Hu, W., Patel, B., Bezwada, D., … Smeal, T. (2015). PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell, 28(1), 70–81. https://doi.org/10.1016/j.ccell.2015.05.010
   PubMed Web of Science ®Google Scholar